Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic <i>ANK3-RET</i> Fusion in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer

Published:2022-07 Issue:6 Volume: Page:
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precision Oncology

Author:

Urbanska Edyta M.¹^ORCID,Sørensen Jens B.¹,Melchior Linea C.²,Costa Junia C.³,Santoni-Rugiu Eric²⁴^ORCID

Affiliation:

1. Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

2. Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

3. Department of Radiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

4. Biotech Research & Innovation Center (BRIC), University of Copenhagen, Copenhagen, Denmark

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.22.00040

Reference26 articles.

1. Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance

2. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

3. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

4. GOPC-ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung Adenocarcinoma

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined Dacomitinib and Selpercatinib Treatment for a Patient with EGFR-Mutant Non-Small Cell Lung Cancer and Acquired CCDC6-RET Fusion;OncoTargets and Therapy;2024-06

2. RET rearrangement as a mechanism of resistance to ALK-TKI in non-small cell lung cancer patient with EML4-ALK fusion: A case report;Heliyon;2024-05

3. Concurrent KRAS p.G12C mutation and ANK3::RET fusion in a patient with metastatic colorectal cancer: a case report;Diagnostic Pathology;2024-03-27

4. Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC;Virchows Archiv;2024-03-16

5. Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC;Frontiers in Oncology;2024-02-07